阿托伐他汀治疗脑梗死的临床效果

Clinical effect of atorvastatin in the treatment of cerebral infarction

目的探讨阿托伐他汀治疗脑梗死的临床效果。方法将2012年12月-2014年12月我院收治的140例脑梗死患者随机分为对照组（70例）和观察组（70例）。对照组予以常规治疗;观察组在常规治疗基础上加用阿托伐他汀。比较两组患者高敏C-反应蛋白（hs-CRP）、基质金属蛋白酶-9（MMP-9）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）水平和NIHSS评分。结果观察组总有效率为94.28%,明显高于对照组的82.86%,差异有统计学意义（P〈0.05）;治疗后,两组患者MMP-9、hs-CRP、TC及LDL-C水平均有不同程度的下降,且观察组治疗后MMP-9、hs-CRP及TC、LDL-C水平明显低于对照组,差异有统计学意义（P〈0.05）;观察组治疗后NIHSS评分明显低于对照组,差异有统计学意义（P〈0.05）。结论阿托伐他汀能降低脑梗死患者hs-CRP、MMP-9、TC和LDL-C的水平,缓解脑梗死患者炎性反应,改善患者的神经缺损功能,值得临床推广应用。

Objective To investigate the effect of atorvastatin in the treatment of cerebral infarction. Methods 140 cases of cerebral infarction in our hospital from December 2012 to December 2014 were randomly divided into the control group（70 cases） and the observation group（70 cases）,the control group was given routine treatment,the observation group was treated with atorvastatin on the basis of conventional therapy,the level of hs-CRP,MMP-9,TC,LDL-C and NIHSS score between two groups were compared. Results The total effective rate of the observation group was 94.28%,significantly higher than 82.86% in the control group,with statistical difference（P〈0.05）;after treatment,the level of MMP-9,hs-CRP,TC and LDL-C in two groups was different degrees of decline respectively and the observation group was significantly lower than that of the control group respectively,with statistical difference（P〈0.05）;after treatment,the NIHSS score of the observation group was significantly lower than that of the control group with statistical difference（P〈0.05）.Conclusion Atorvastatin can reduce the cerebral infarction patients with hs-CRP,MMP-9,TC and LDL-C level,alleviate cerebral infarction patients with inflammatory reaction,improve the neurologic function in patients.It is worthy of clinical popularization and application.